West Pharmaceutical Services ( (WST) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
West Pharmaceutical Services’ stock took a hit, dropping sharply by 38% after its 2025 profit and revenue forecast missed Wall Street expectations. The company blamed the shortfall on a strong dollar and clients cutting inventory levels. However, the firm’s Q4 results exceeded expectations with a 2.3% increase in net sales, driven by strong demand for high-value products like self-injection devices. In response, analysts have revised their price targets: Deutsche Bank upgraded the stock to Buy, seeing the current price as a good entry point for a stable investment; Bank of America maintained a Buy rating, citing the company’s robust market position and growth plans; while KeyBanc lowered its price target due to the disappointing FY25 guidance but kept an Overweight rating based on long-term confidence in the company.
More about West Pharmaceutical Services
YTD Price Performance: -39.18%
Average Trading Volume: 565,244
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.42B
For further insights into WST stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.